Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Research In Motion Ltd (BBRY), Tibco Software Inc. (TIBX), Splunk Inc (SPLK): Why Did My Stock Just Die?

The market can’t decide whether the EU taking cash from individual Cypriot depositors to stave off a default by the government is a good thing or not. On Friday, the Dow Jones Industrial Average rose 90 points on the prospects a deal would be hammered out, and in midday trading today the index was falling because they actually agreed to it. Seizing the bank accounts is a harsh penalty for individuals who didn’t contribute to the financial calamity and depositors everywhere have to be calculating the risk for a similar raid on their own accounts.

Research In Motion Ltd. (NASDAQ:BBRY)The three stocks below faced a run of a different sort as investors turned tail, but this could just be a temporary situation. Let’s first see whether they had good reason to fall as panic-fueled routs can sometimes lead to excellent buying opportunities.

Company Change
Tibco Software Inc. (NASDAQ:TIBX) (9.4%)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (8.1%)
Research In Motion Ltd (NASDAQ:BBRY) (7.7%)

Big expectations
Investors are hoping big data is as much of a big deal as enterprise software vendor TIBCO Software says it will be, because quarterly revenues came up well short of expectations, sending its stock sharply lower on Friday.

There might be something to management’s confidence, though, because its optimization products saw a 37% jump in sales in the quarter, indicating there will be future growth there, too. But the software specialist still had a hard time putting behind it the very weak results it recorded in licensing, where sales fell 5%. Guidance, however, suggests licensing revenue will be down another 10% in the second quarter.

While it booked over 100 new deals worth $100,000 or more, the dozen it booked worth $1 million or more was down from the 20 such lucrative deals it recorded last year, so there’s a lot of distance to go yet to shore up the shortfall. And analysts just don’t see big changes on the horizon for TIBCO, downgrading their outlooks for the stock even if they maintained their ratings. Some of those were cut as well because competitive pressure from International Business Machines Corp. (NYSE:IBM) and Oracle Corporation (NASDAQ:ORCL) is piling up such that up-and-comers like Splunk Inc (NASDAQ:SPLK) are viewed as better options for playing big data.

After coming up short last quarter and blaming its North American president for the problem (and then sacking him), I suggested TIBCO was suffering from problems greater than just one person and any turnaround would probably take more than one quarter to work itself out. After reviewing the current quarter’s results, I’m not sure TIBCO has proven it’s ready to turn around just yet.

Give and take
Easy come, easy go. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was up 24% the other day on data that was essentially a rehash of what investors already knew, so we shouldn’t be surprised that they might have used the opportunity to take some profits off the table on Friday. That the decline was of a smaller magnitude than the rise, however, at least gives investors some room — and money — to play with.

The Fool’s Brian Orelli isn’t one who thinks it’s time to climb on the bandwagon just yet, though. Because the stock surge was based on previously reported data for pimavanserin, the big jump last week means that investors were worried there might have been some unpleasant surprises lurking in the shadows. The company has two failures for Parkinson’s already to its name, so being skeptical might have been the wise move.

Brian’s not convinced there’s not a lot of rough road ahead for ACADIA, and with antipsychotics already on the market being prescribed off-label, even a successful navigation of the clinical trial maze might not be enough to get it going. Yet as I noted last week, a drug specifically targeting a disorder might still gain plenty of traction, so I wouldn’t give up on ACADIA just yet.

A black eye for Research In Motion Ltd (NASDAQ:BBRY)
Given all the hype and anticipation built into the resurrection of Research In Motion Ltd (NASDAQ:BBRY)’s new smartphone and operating system, how could it do anything but disappoint investors?

Research In Motion (BBRY)

The new Z10 was expected to launch with a lot of fanfare, but a report in Friday’s Wall Street Journal suggested that rather than bunting and balloons for the smartphone, the reception has been more of a shrug. There’s no real incentive to move to the new BlackBerry: it’s comparably priced to the iPhone and Android devices already on the market and the new software isn’t that compelling to make anyone want to switch.

I said last year as the hype was building that this was Research In Motion Ltd (NASDAQ:BBRY)’s Hail Mary pass. It might be too soon to tell whether the ball’s been caught, but there’s a lot of bobbling going on. Right now, it looks like the clock has run out on Research In Motion Ltd (NASDAQ:BBRY). The buyout rumor that got everyone excited the other day may still be its last best hope.

The article Why Did My Stock Just Die? originally appeared on Fool.com.

Fool contributor Rich Duprey owns shares of Oracle. The Motley Fool recommends TIBCO Software. The Motley Fool owns shares of International Business Machines (NYSE:IBM) and Oracle.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...